News & Events

• Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
  Published on 2022-09-22
• Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
  Published on 2022-09-08
• Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
  Published on 2022-09-07
• Genetic Analysis appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
  Published on 2022-09-01
• CORRECTION: Interim report January – June 2022
  Published on 2022-08-18
• Interim report January – June 2022
  Published on 2022-08-18
• Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
  Published on 2022-08-04
• Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
  Published on 2022-08-03
• Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
  Published on 2022-07-28
• Vedanta Biosciences to Present at Upcoming Investor Conferences
  Published on 2022-07-07
• Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
  Published on 2022-06-30
• Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
  Published on 2022-06-28
• Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
  Published on 2022-06-28
• Genetic Analysis and Servatus enter Strategic Collaboration Agreement to develop new microbiome diagnostic and therapeutic solutions
  Published on 2022-06-22
• Norne Securities initiates coverage of Genetic Analysis
  Published on 2022-06-16